Category: Psychedelic Bulletin

Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT Roll-Out; Psychedelics at SXSW; Could MDMA Be Among First Beneficiaries of Faster UK Drug Approvals?

Psychedelic Bulletin #132: COMPASS Pathways Amends Phase 3 Program; Stamets Stack Finally Patented; Learning from Zuranolone?

Psychedelic Bulletin #131: Study Turns Understanding of Psychedelic-Induced Neuroplasticity Inside Out; EU Regulators Show Interest in Psychedelics; What Next for At-Home Ketamine Therapy?

Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A

Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT ‘Mebufotenin’

Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study “Successful”; New York Bill Would Legalize Psychedelics; Oregon Begins Accepting Licence Applications

Psychedelic Bulletin #127: Psilocybin Shows Promise in Bipolar Disorder; Gilgamesh Raises $39m; California Decrim. Bill Returns; Canadian Province Covers Cost of PAT

Psychedelic Bulletin #126: Journey’s Mescaline Patent Pledge; Therapeutic Alliance Doesn’t Predict Response to Psilocybin Therapy, Says COMPASS

Psychedelic Bulletin #125: New Data Boosts Spravato’s Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas

Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing for atai’s PCN-101 Results; Tactogen Launches Community Funding Round

Weekly Bulletin

Research Review

News & Interviews

Psychedelics Patent Trackers

Psychedelic Legalization & Decriminalization Tracker

Psychedelics Drug Development Tracker

Stocks & Companies Directory

Sector Landscape Map

Stock Watchlist

Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT Roll-Out; Psychedelics at SXSW; Could MDMA Be Among First Beneficiaries of Faster UK Drug Approvals?

Psychedelic Bulletin #132: COMPASS Pathways Amends Phase 3 Program; Stamets Stack Finally Patented; Learning from Zuranolone?

Psychedelic Bulletin #131: Study Turns Understanding of Psychedelic-Induced Neuroplasticity Inside Out; EU Regulators Show Interest in Psychedelics; What Next for At-Home Ketamine Therapy?

Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A

Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT ‘Mebufotenin’

Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study “Successful”; New York Bill Would Legalize Psychedelics; Oregon Begins Accepting Licence Applications

Psychedelic Bulletin #127: Psilocybin Shows Promise in Bipolar Disorder; Gilgamesh Raises $39m; California Decrim. Bill Returns; Canadian Province Covers Cost of PAT

Psychedelic Bulletin #126: Journey’s Mescaline Patent Pledge; Therapeutic Alliance Doesn’t Predict Response to Psilocybin Therapy, Says COMPASS

Psychedelic Bulletin #125: New Data Boosts Spravato’s Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas

Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing for atai’s PCN-101 Results; Tactogen Launches Community Funding Round

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.